MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST001186/mwtabprimaryOK200MetabolomicsMass SpectrometryESIHuntingtons DiseaseMus Musculushttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST001186Time:3 | Treatment:Dimethyl fumarateTime:1 | Treatment:4-DeoxypyridoxineTime:1 | Treatment:Sodium ButyrateTime:2 | Treatment:Trichostatin ATime:3 | Treatment:CyproheptadineTime:3 | Treatment:LoxapineTime:2 | Treatment:Q111SST_ControlTime:1 | Treatment:SelisistatTime:3 | Treatment:Trichostatin ATime:2 | Treatment:CyproheptadineTime:1 | Treatment:ClioquinolTime:1 | Treatment:Q7SST_ControlTime:1 | Treatment:HaloperidolTime:3 | Treatment:CysteamineTime:2 | Treatment:4-DeoxypyridoxineTime:1 | Treatment:CyproheptadineTime:2 | Treatment:Fingolimod phosphateTime:2 | Treatment:PizotifenTime:2 | Treatment:LoxapineTime:1 | Treatment:Trichostatin ATime:3 | Treatment:Diacylglycerol kinase inhibitor IITime:2 | Treatment:Sodium ButyrateTime:1 | Treatment:PizotifenTime:3 | Treatment:HaloperidolTime:3 | Treatment:ClioquinolTime:2 | Treatment:CysteamineTime:2 | Treatment:Diacylglycerol kinase inhibitor IITime:3 | Treatment:MeclizineTime:1 | Treatment:Dimethyl fumarateTime:1 | Treatment:MeclizineTime:1 | Treatment:LoxapineTime:3 | Treatment:SelisistatTime:3 | Treatment:PizotifenTime:1 | Treatment:NortriptylineTime:2 | Treatment:MeclizineTime:1 | Treatment:Q111SST_ControlTime:3 | Treatment:4-DeoxypyridoxineTime:2 | Treatment:NicotinamideTime:3 | Treatment:Sodium ButyrateTime:1 | Treatment:CysteamineTime:2 | Treatment:NortriptylineTime:2 | Treatment:Q7SST_ControlTime:3 | Treatment:Fingolimod phosphateTime:3 | Treatment:NicotinamideTime:1 | Treatment:Diacylglycerol kinase inhibitor IITime:1 | Treatment:Fingolimod phosphateTime:2 | Treatment:Dimethyl fumarateTime:2 | Treatment:SelisistatTime:3 | Treatment:NortriptylineTime:2 | Treatment:ClioquinolTime:3 | Treatment:Q111SST_ControlTime:1 | Treatment:NicotinamideTime:3 | Treatment:Q7SST_ControlTime:2 | Treatment:HaloperidolCultured CellsMassachusetts Institute of TechnologyNormal phase POSITIVE ION MODE. Normal phase NEGATIVE ION MODE. HILIC POSITIVE ION MODE. HILIC NEGATIVE ION MODE.MetabolomicsWorkbenchpreventive measures, Controlling, preventive therapy, reference sample, control, prophylaxis, Metabonomic, Cell., Metabonomics, Metabolomic, prevention and control, Cell, Controlled, preventionaverage, average.falseUntargeted metabolomics on control and compound-treated STHdhQ111 cells and control STHdhQ7 cellsST00118610090